BidaskClub upgraded shares of Cardiovascular Systems (NASDAQ:CSII) from a strong sell rating to a sell rating in a report published on Thursday.

A number of other equities research analysts also recently commented on the stock. William Blair reaffirmed a market perform rating on shares of Cardiovascular Systems in a research report on Thursday, December 21st. Needham & Company LLC downgraded shares of Cardiovascular Systems from a buy rating to a hold rating and cut their target price for the stock from $33.11 to $23.00 in a research report on Friday, December 15th. Raymond James Financial reaffirmed a hold rating on shares of Cardiovascular Systems in a research report on Monday, December 4th. Zacks Investment Research raised shares of Cardiovascular Systems from a sell rating to a hold rating in a research report on Monday, November 13th. Finally, Citigroup assumed coverage on shares of Cardiovascular Systems in a research report on Thursday, September 21st. They issued a market perform rating for the company. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company’s stock. Cardiovascular Systems presently has an average rating of Hold and an average target price of $31.50.

Shares of Cardiovascular Systems (NASDAQ CSII) traded up $0.06 on Thursday, hitting $23.88. 113,700 shares of the company traded hands, compared to its average volume of 166,725. The company has a quick ratio of 3.83, a current ratio of 4.30 and a debt-to-equity ratio of 0.18. Cardiovascular Systems has a 12 month low of $23.00 and a 12 month high of $33.11. The company has a market capitalization of $792.72, a P/E ratio of -398.00 and a beta of 2.52.

Cardiovascular Systems (NASDAQ:CSII) last posted its earnings results on Wednesday, October 25th. The medical device company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. The business had revenue of $49.70 million during the quarter, compared to the consensus estimate of $51.00 million. During the same quarter in the previous year, the firm posted ($0.06) EPS. The firm’s revenue was down .2% on a year-over-year basis. equities analysts predict that Cardiovascular Systems will post -0.03 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. boosted its stake in shares of Cardiovascular Systems by 0.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 201,992 shares of the medical device company’s stock worth $6,511,000 after acquiring an additional 1,680 shares during the last quarter. First Trust Advisors LP purchased a new position in shares of Cardiovascular Systems during the 2nd quarter worth $2,103,000. Bank of New York Mellon Corp boosted its stake in shares of Cardiovascular Systems by 15.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 209,029 shares of the medical device company’s stock worth $6,738,000 after acquiring an additional 27,539 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Cardiovascular Systems by 2.9% during the 2nd quarter. Legal & General Group Plc now owns 7,763 shares of the medical device company’s stock worth $249,000 after acquiring an additional 216 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Cardiovascular Systems by 160.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,135 shares of the medical device company’s stock worth $166,000 after acquiring an additional 3,165 shares during the last quarter. 74.86% of the stock is owned by institutional investors and hedge funds.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/cardiovascular-systems-csii-upgraded-to-sell-by-bidaskclub/1798639.html.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with Analyst Ratings Network's FREE daily email newsletter.